Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry
Michael J
MJ
Mulley
Albert J
AJ
D014408:Biomarkers, Tumor / Q000097:blood*; D055088:Early Detection of Cancer; D006801:Humans; D015994:Incidence; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening / Q000009:adverse effects* / Q000379:methods; D015233:Models, Statistical; D008962:Models, Theoretical; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology / Q000401:mortality* / Q000517:prevention & control / Q000628:therapy; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014481:United States / Q000453:epidemiology; D019564:Unnecessary Procedures
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen